Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04781075 · ClinicalTrials.gov registry record · Phase 4
Modified TAP (Transverse Abdominis Plane) Block in Colorectal Surgery
A Phase 4 study, sponsored by Ochsner Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT04781075 is a Phase 4 study that has completed, run by Ochsner Health System. The registered enrollment target is 76 participants.
The verdict
NCT04781075, a Phase 4 study, has completed, sponsored by Ochsner Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
Single Blind, Randomized Controlled study to see if TAP Block with Exparel provides better pain relief than TAP Block with bupivicaine. Differences in Pain Scale, Length of Stay, and Total Narcotic use in the hospital will be evaluated.
Interventions
- DRUG Bupivacaine Injection
- DRUG Exparel Injectable Product
- OTHER Pain Scale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04781075
The ClinicalTrials.gov registry entry for NCT04781075 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ochsner Health System, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bupivacaine Injection is the first listed.
NCT04781075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04781075 about?
NCT04781075 is a clinical study titled "Modified TAP (Transverse Abdominis Plane) Block in Colorectal Surgery". Single Blind, Randomized Controlled study to see if TAP Block with Exparel provides better pain relief than TAP Block with bupivicaine. Differences in Pain Scale, Length of Stay, and Total Narcotic use in the hospital will be evaluated.
What is the current status of trial NCT04781075?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2017-12-01. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04781075?
The interventions under investigation include: Bupivacaine Injection (DRUG), Exparel Injectable Product (DRUG), Pain Scale (OTHER).
Who is sponsoring clinical trial NCT04781075?
This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.